If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Recent changes in Moscow's regional climate are often cited by climate scientists as evidence of global warming, since the city is in the middle latitudes of the Northern Hemisphere; however, by definition, climate change is global, not regional. During the summer, very high temperatures are often recorded in the city (in 2001, 2002, 2003, 2010, 2011, and 2021). Along with the southern part of Central Russia, after recent years of hot summer seasons, Moscow's climate shows hot-summer classification trends. Winter has also become significantly milder: for example, the average January temperature in the early 1900s was −12.0 °C (10.4 °F), while it is currently about −7.0 °C (19.4 °F). The end of January–February is often colder, with frosts reaching −30.0 °C (−22.0 °F) a few nights per year (in 2006, 2010, 2011, 2012, and 2013). As of 2024, the most recent decade was the warmest in the history of meteorological observations of Moscow. Temperature changes in the city are shown in the table below:
Some mushrooms are used in folk medicine. In a few countries, extracts, such as polysaccharide-K, schizophyllan, polysaccharide peptide, or lentinan, are government-registered adjuvant cancer therapies, but clinical evidence for efficacy and safety of these extracts in humans has not been confirmed. Although some mushroom species or their extracts may be consumed for therapeutic effects, some regulatory agencies, such as the US Food and Drug Administration, regard such use as a dietary supplement, which does not have government approval or common clinical use as a prescription drug.
Most infants with CMD will display some progressive muscle weakness or muscle wasting (atrophy), although there can be different degrees and symptoms of severeness of progression. The weakness is indicated as hypotonia, or lack of muscle tone, which can make an infant seem unstable. Eventually, most patients develop joint contractures or fixed joint deformities. Children may be slow with their motor skills; such as rolling over, sitting up or walking, or may not even reach these milestones of life. Some of the rarer forms of CMD can result in significant learning disabilities.
Sources: en.wikipedia.org
The film has won the Gen Art Acura Grand Jury Prize 2008, the Asian American International Film Festival Best Feature Film Award, the San Francisco International Asian American Film Festival Best Narrative Feature Award, and the Visionary Award at Calgary's Fairy Tales International. It was also nominated for the Tokyo Grand Prix at the Tokyo International Film Festival.
The cooling trend since the mid-Holocene thermal maximum is consistent with ice core and pollen records, but the corresponding magnitude of cooling is elusive due to complicated influences from local effects such as humidity and soil water composition. The meaning of isotopes in cellulose and its applications is still an area of active study.
The socialists proposed the full integration of Spain into Europe, but when they took office the negotiations for the accession to the European Economic Community (EEC) were still blocked because of the "pause" in the enlargement imposed by the French president Giscard d'Estaing. However, the triumph in the presidential elections of the socialist François Mitterrand allowed rapid progress in the negotiations and so on June 12, 1985, the EEC accession treaty was signed and on January 1, 1986, Spain joined the EEC together with Portugal.
In the diet, β-glucans are a source of soluble, fermentable fiber – also called prebiotic fiber – which provides a substrate for microbiota within the large intestine, increasing fecal bulk and producing short-chain fatty acids as byproducts with wide-ranging physiological activities. This fermentation impacts the expression of many genes within the large intestine, which further affects digestive function and cholesterol and glucose metabolism, as well as the immune system and other systemic functions.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.